PMID: 6159445Nov 1, 1980Paper

Antigenic specificity of the cytolytic T lymphocyte response to murine sarcoma virus-induced tumors. III. Characterization of cytolytic T lymphocyte clones specific for Moloney leukemia virus-associated cell surface antigens

The Journal of Experimental Medicine
A WeissJ C Cerottini

Abstract

Cytolytic T lymphocyte (CTL) clones specific for Moloney leukemia virus (MoLV)-derived tumor cells were generated by placing limiting numbers of C57BL/6 responder cells into mixed leukocyte-tumor cell microcultures. Under appropriate conditions (presence of stimulating tumor cells, accessory cells, and T cell growth factor), such cloned CTL could readily be expanded to provide large numbers of homogeneous, highly cytolytic CTL populations for further characterization. Using four target-cell types, three specificity patterns were observed: one reactive with the syngeneic MoLV-derived tumor only, one cross-reactive with an allogeneic MoLV-derived tumor, and one cross-reactive with normal allogeneic cells. Subclones derived from these three types of clones exhibited a high degree of stability in terms of lytic activity and specificity over a 4-mo period of observation. Three clones analyzed by flow cytofluorometry using monoclonal antibodies were all found to be of the Lyt-1+2+ phenotype. Furthermore, lysis of target cells by all of six clones tested was inhibited by anti-H-2Db (but not by anti-H-2Kb) monoclonal antibodies, demonstrating H-2Db-restriction at the clonal level.

References

Apr 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·E NakayamaL J Old
Dec 1, 1979·The Journal of Experimental Medicine·T Taniyama, H T Holden
Feb 15, 1977·International Journal of Cancer. Journal International Du Cancer·F Plata, B Sordat
Jan 1, 1979·Immunological Reviews·J A Ledbetter, L A Herzenberg
Mar 1, 1976·The Journal of Experimental Medicine·J W Schrader, G M Edelman
Jun 1, 1976·The Journal of Experimental Medicine·M A Skinner, J Marbrook
Apr 1, 1980·The Journal of Experimental Medicine·A L Glasebrook, F W Fitch

❮ Previous
Next ❯

Citations

Jan 1, 1986·Immunogenetics·P Pala, B A Askonas
Jul 30, 1982·Journal of Immunological Methods·W Haas, H Von Boehmer
Jun 1, 1982·The Journal of Experimental Medicine·D H Raulet, M J Bevan
Mar 1, 1982·Immunobiology·H R MacDonaldC Bron
Apr 1, 1986·Journal of Immunogenetics·K HuiF G Grosveld
Jan 1, 1983·Immunological Reviews·A SilvaM Nabholz
Aug 15, 1981·International Journal of Cancer. Journal International Du Cancer·K SugamuraY Hinuma
Sep 1, 1983·European Journal of Immunology·N ChristensenJ Marbrook
May 8, 1993·International Journal of Cancer. Journal International Du Cancer·T Boon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.